ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

c-Met Inhibitor ANS014004

Also written as “ANS014004” and “ANS014004 + PLB1004”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageC-Met Inhibitor ANS014004: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 27, 20243 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Avistone Biotechnology22 open or runningphase 1since Feb 27, 2024Feb 27, 2024Apr 2027phase 1 · NCT06307795
Beijing Pearl Biotechnology Limited Liabilityits history only11 open or runningphase 2since Nov 4, 2025Nov 4, 2025Dec 2029phase 2 · NCT07285148

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Avistone Biotechnology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2024First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsFirst studyNCT06328439 · 40 enrolled · China
  2. Mar 5, 2024Phase 1 study in Locally Advanced or Metastatic Solid TumorsNCT06307795 · 63 planned · United States, Canada, China

Ahead

  1. Apr 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsNCT06307795
  2. Dec 31, 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsNCT06328439

TargetBeta

MET →read by rule
“An orally bioavailable, next-generation, type II inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibruleBeijing Pearl Biotechnology Limited Liabilityphase 39
glumetinibruleHaihe Biopharmaphase 38
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27

Studies

All 2 Avistone Biotechnology leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06307795Locally Advanced or Metastatic Solid Tumors · United States, Canada, China1RecruitingApr 202763
NCT06328439Locally Advanced or Metastatic Solid Tumors · China1Active, not recruitingDec 31, 202740

How it is read

Names in the registry

  • “ANS014004”, 2 entries
  • “ANS014004 + PLB1004”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.